Incyte (INCY) Aktie Kurs
Incyte Kurs
Under de senaste 19 åren växte Incyte intäkterna med 31,7 % årligen och nådde 5,14 Mrd USD. Vinst per aktie har vuxit med 68,6 % per år under de senaste 10 åren. För Incyte är nettovinstmarginal på 25,0 % ned jämfört med 31,8 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Incyte är 130,00 USD, cirka över kursen med 14,8 %. Av 35 analytiker ger 18 köpråd — den samlade bedömningen är Köp.
Incyte aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Incyte affärsmodell och aktieanalys
Vanliga frågor om Incyte-aktien
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 128,38 USD för Incyte-aktien (median: 130,00 USD), vilket innebär +13,4 % mot senaste kurs. Konsensus baseras på 35 analytikerbetyg.
35 analytiker betygsätter för närvarande Incyte-aktien: 18 rekommenderar köp, 17 behåll och 0 sälj. För 2026 väntar sig analytiker att Incyte genererar intäkter på 5,93 Mrd USD och vinst per aktie på 3,11 USD.
Omräknat till aktuell växelkurs handlas Incyte-aktien till 101,24 EUR (113,25 USD).
Incyte-aktien (INCY) är noterad på 8 börser, bland annat: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
Omsättningen för förväntad Incyte är 5,93 Mrd USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Incyte är 637,41 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Incyte är för närvarande 36,38. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Incyte-aktien.
Kurs-försäljningskvoten (P/S) för Incyte är för närvarande 3,91. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Incyte-aktien.
Eulerpool Quality Score för Incyte är 6/10.
ISIN för Incyte är US45337C1027. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Incyte är 896133. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Incyte är INCY. Tickersymbolen används för att handla Incyte-aktier på börsen.
Incyte aktie
Incyte Jämförbar grupp
Incyte Ticker
Incyte FIGI
Alla nyckeltal och djupgående analys av Incyte
Vår aktieanalys av Incyte-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Incyte. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: